European Myeloma Network (EMN) Sample Project

Launched by EUROPEAN MYELOMA NETWORK B.V. · Jan 25, 2024

Keywords

ClinConnect Summary

The European Myeloma Network (EMN) Sample Project is a clinical study focused on collecting and analyzing biological samples from patients with conditions related to multiple myeloma, including smoldering multiple myeloma, plasma cell leukemia, and MGUS. This study aims to create a standardized system across different centers in Europe to gather important clinical information and biological samples from patients both at the start of their treatment and throughout their care. By doing this, researchers hope to improve understanding and treatment of these conditions.

To participate, individuals must be at least 18 years old and have a diagnosis of MGUS, smoldering multiple myeloma, or multiple myeloma, among other related conditions. Participants should not have received prior anti-myeloma treatments, except in urgent situations, and must be able to provide informed consent, meaning they understand the study and agree to take part. Those who join the study can expect to provide biological samples, such as blood, which will be collected and stored for future research. This trial is currently recruiting participants, and it’s important for anyone considering joining to feel comfortable discussing their eligibility and any questions they may have with their healthcare team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD)
• • Subjects are ≥ 18 years old.
• • Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures.
• • 1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and
• • 2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.
• Exclusion Criteria:
• • Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care).
• • Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events.
• • Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.